Navigation Links
Cephalon Conference Call Invitation
Date:5/5/2008

Tuesday, May 6, 2008, 5:30 p.m. U.S. EDT

FRAZER, Pa., May 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced plans to host an investor conference call at 5:30 p.m. EDT on May 6, 2008 to discuss the U.S. Food and Drug Administration advisory committee panel meeting held that day. The advisory committee panel is considering the company's supplemental New Drug Application for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain.

May 6, 2008 Schedule

5:20 p.m. EDT To participate in the conference call, dial 913-312-0407

and refer to Conference Code Number 2046179

5:30 p.m. EDT Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information" then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EDT, May 20, 2008. To listen to the audio replay, dial 719- 457-0820 and use the Conference Code Number 2046179.

Additional information presented on the conference call may be made available on the Investor Information page of the company's website.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cephalon Reports Strong First Quarter Earnings
2. Cephalon Appoints Gerald J. Pappert as General Counsel
3. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
4. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
5. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
7. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
8. United American Healthcare Corporation to Host Fiscal 2008 Third Quarter Results Conference Call May 13th
9. Digirad Corporation to Present at Bank of America 2008 Health Care Conference
10. Zimmer Holdings to Present at Deutsche Bank 33rd Annual Health Care Conference
11. American Pacific to Release Financial Results and Hold Fiscal 2008 Second Quarter Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... Digital Scientists, a software innovation lab specializing in web design and ... Carolina location. The lab has set up shop at the renowned NEXT Innovation ... Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ CEO, ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... 23, 2017 The key factors driving ... diabetic population, accelerating economic growth and increasing healthcare expenditure. Some ... higher life expectancy of ESRD patients, rising demand for home ... the expansion of the market is hindered by high treatment ... ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology: